ICYMI: Lack Of Competition In Drug Market Drives Up Medicare & Medicaid Spending

03-18-2019 Blog Posts

In case you missed it, the Centers for Medicare and Medicaid Services (CMS) released new data last week which showed that prescription drugs with only one manufacturer are responsible for the biggest spending increases in both Medicare and Medicaid. According to the data, overall spending on prescription drugs under Medicare Part D increased at an […]

Good Medicine: Congress Should Pass Market-Based Solutions to Spur Prescription Drug Competition

03-13-2019 Blog Posts

The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act and the Fair Access for Safe and Timely (FAST) Generics Act are being discussed in a legislative hearing today before the U.S. House Energy & Commerce Subcommittee on Health.  The solutions contained in these market-based measures represent critical steps toward lowering prescription drug prices […]

CSRxP: Legislative Hearing on Drug Pricing Bills a Positive First Step, Now More Action Needed

03-13-2019 Press Release

Today, members of the U.S. House Committee on Energy & Commerce Subcommittee on Health held a legislative hearing on a number of proposals to tackle skyrocketing drug prices, more evidence of building momentum in Congress to take concrete action. “Today’s hearing was an important first step toward passing bipartisan, market-based solutions like the CREATES Act […]

Second Opinion: Rebate Rule Will Hike Premiums On Seniors

03-12-2019 Blog Posts

Lowering prescription drug prices is a laudable focus of the Trump Administration, and the Campaign for Sustainable Rx Pricing (CSRxP) supports several measures put forward by the administration, including getting more generics and biosimilars into the market to spur competition, increasing drug price transparency and cracking down on anti-competitive practices from big pharmaceutical manufacturers. But […]

Questioning The Rebate Rule

03-12-2019 Press Release

Secretary Azar Recently Noted The Effectiveness Of PBMs Now Targeted By Agency Proposal U.S. Department of Health and Human Services (HHS) Secretary Alex Azar will head to Capitol Hill on Tuesday where he will testify on the Trump Administration’s budget proposal before the U.S. House Committee on Energy and Commerce Subcommittee on Health.  During his […]

Trump Administration Should Focus on Market-Based Solutions to Alleviate Drug Prices

03-11-2019 Press Release

As Secretary Azar Heads To Capitol Hill, CSRxP Encourages Lawmakers To Question Budget-Busting $200 Billion Rebate Rule For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Monday ahead of U.S. Department of Health and Human Services Secretary Alex Azar testifying Tuesday on the […]

Headlines: Lawmakers, Patients, Experts Keep-Up Drumbeat For Action On Drug Prices

03-9-2019 Blog Posts

Three More Congressional Hearings Tackle Big Pharma’s Anti-Competitive Practices   This week, the U.S. Senate Special Committee on Aging, U.S. House Ways & Means Subcommittee on Health and U.S. House Judiciary Subcommittee on Antitrust kept up the pace of activity on prescription drug pricing with a series of hearings on the issue. Members of Congress […]

ICYMI: House Judiciary Subcommittee on Anti-Trust Members Tout Benefits of CREATES Act

03-8-2019 Blog Posts

During today’s House Judiciary Subcommittee on Anti-trust hearing on healthcare consolidations – Members of Congress recognized Big Pharma’s continued role in price gouging American patient through patent abuse schemes to hinder generic competition and maintain monopolies over their biggest money makers. Importantly, key members of the committee used the hearing as an opportunity to tout the benefits […]

THEY SAID IT! U.S. House Ways & Means Subcommittee Pushes For Increased Competition To Lower Drug Prices

03-8-2019 Press Release

For Immediate Release  Contact: Jon Conradi 860-235-3884 [email protected] On Thursday, members of the U.S. House Committee on Ways and Means Subcommittee on Health added their voice to the building momentum for action in Washington to bring down the out-of-control price of prescription drugs.  Committee members, of both parties, further agreed swift action is needed to […]

Skyrocketing Drug Prices Place Extreme Financial Burdens On Families

03-7-2019 Press Release

Patients Tell Congress, Paying For Life-Saving Medications Often Means Going Without Basic Needs & Going Into Debt  Five patients testified before the U.S. Senate Special Committee on Aging Wednesday to tell their harrowing stories of how skyrocketing drug prices have impacted their lives and their finances.  This is the first of three hearings this week […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.